S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Bank Accounts: Frozen! (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
Bank Accounts: Frozen! (Ad)
Travel disruption hits Germany on eve of transport strike
Berlin climate proposal fails to get enough yes votes to win
Bank Accounts: Frozen! (Ad)
Adele extends Las Vegas residency, plans concert film
Turkmenistan votes for new, opposition-free parliament
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Bank Accounts: Frozen! (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
Bank Accounts: Frozen! (Ad)
Travel disruption hits Germany on eve of transport strike
Berlin climate proposal fails to get enough yes votes to win
Bank Accounts: Frozen! (Ad)
Adele extends Las Vegas residency, plans concert film
Turkmenistan votes for new, opposition-free parliament
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Bank Accounts: Frozen! (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
Bank Accounts: Frozen! (Ad)
Travel disruption hits Germany on eve of transport strike
Berlin climate proposal fails to get enough yes votes to win
Bank Accounts: Frozen! (Ad)
Adele extends Las Vegas residency, plans concert film
Turkmenistan votes for new, opposition-free parliament
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Bank Accounts: Frozen! (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
Bank Accounts: Frozen! (Ad)
Travel disruption hits Germany on eve of transport strike
Berlin climate proposal fails to get enough yes votes to win
Bank Accounts: Frozen! (Ad)
Adele extends Las Vegas residency, plans concert film
Turkmenistan votes for new, opposition-free parliament
NASDAQ:ESPR

Esperion Therapeutics - ESPR Stock Forecast, Price & News

$1.60
+0.04 (+2.56%)
(As of 03/24/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.52
▼
$1.74
50-Day Range
$1.46
▼
$7.17
52-Week Range
$1.26
▼
$8.87
Volume
8.13 million shs
Average Volume
7.84 million shs
Market Capitalization
$122.51 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.17

Esperion Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.22 Rating Score
Upside/​Downside
597.9% Upside
$11.17 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-2.76
Upright™ Environmental Score
News Sentiment
-0.06mentions of Esperion Therapeutics in the last 14 days
Based on 15 Articles This Week
Insider Trading
Selling Shares
$125,227 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.34) to $0.10 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.47 out of 5 stars

Medical Sector

181st out of 1,005 stocks

Pharmaceutical Preparations Industry

75th out of 486 stocks

See Top Rated MarketRank™ Stocks Here

ESPR stock logo

About Esperion Therapeutics (NASDAQ:ESPR) Stock

Esperion Therapeutics, Inc. is a pharmaceutical company. It engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.

Receive ESPR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Esperion Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ESPR Stock News Headlines

March 24, 2023 | markets.businessinsider.com
Analysts Have Conflicting Sentiments on These Healthcare Companies: Esperion (ESPR) and Elevance Health (ELV)
March 23, 2023 | finance.yahoo.com
Esperion Therapeutics (ESPR) Down 74.3% Since Last Earnings Report: Can It Rebound?
March 26, 2023 | Weiss Ratings (Ad)
Bank Accounts: Frozen!
In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!
March 23, 2023 | finanznachrichten.de
Esperion Therapeutics, Inc.: Esperion Announces Closing of $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
March 22, 2023 | finance.yahoo.com
Esperion Announces Closing of $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
March 22, 2023 | americanbankingnews.com
Sheldon L. Koenig Sells 6,999 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) Stock
March 22, 2023 | americanbankingnews.com
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives $11.17 Consensus Target Price from Brokerages
March 22, 2023 | americanbankingnews.com
Q1 2023 EPS Estimates for Esperion Therapeutics, Inc. (NASDAQ:ESPR) Decreased by Analyst
March 26, 2023 | Weiss Ratings (Ad)
Bank Accounts: Frozen!
In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!
March 20, 2023 | finance.yahoo.com
Esperion Announces $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
March 18, 2023 | americanbankingnews.com
Esperion Therapeutics (NASDAQ:ESPR) Rating Reiterated by HC Wainwright
March 18, 2023 | investing.com
Esperion Therapeutics Inc (ESPR)
March 17, 2023 | finance.yahoo.com
5 big analyst cuts: First Republic stock slashed on 'unprecedented uncertainty' | Pro Recap
March 17, 2023 | finance.yahoo.com
Esperion (ESPR) Plummets 54% Over Milestone Payment Row
March 16, 2023 | msn.com
B of A Securities Downgrades Esperion Therapeutics (ESPR)
March 16, 2023 | markets.businessinsider.com
Why Esperion Therapeutics Stock Is Tanking Thursday
March 16, 2023 | msn.com
Esperion Tanks after Dispute with Daiichi Sankyo
March 16, 2023 | benzinga.com
What 11 Analyst Ratings Have To Say About Esperion Therapeutics
March 16, 2023 | finance.yahoo.com
Esperion’s stock tumbles after disclosing dispute about milestone payment
March 16, 2023 | investorplace.com
Why Is Esperion Therapeutics (ESPR) Stock Down 60% Today?
March 15, 2023 | benzinga.com
President and CEO at Esperion Therapeutics Acquires Company Stock Options Worth 445,000 Shares
March 15, 2023 | benzinga.com
Chief Commercial Officer at Esperion Therapeutics Acquires Company Stock Options Worth 94,500 Shares
March 15, 2023 | benzinga.com
Esperion Therapeutics General Counsel Awarded $336K Worth of Stock Options
March 10, 2023 | finance.yahoo.com
Esperion Therapeutics (ESPR) Down 24% in a Week: Here's Why
March 8, 2023 | finance.yahoo.com
International Lipid Expert Panel (ILEP) Recommends Use of Bempedoic Acid Ahead of PCSK9 Inhibitors in Managing Lipid Disorders and Cardiovascular Risk
March 7, 2023 | msn.com
Esperion upgraded at Credit Suisse despite selloff after Nexletol data
March 6, 2023 | msn.com
Esperion Therapeutics Stock Is Diving: What's Going On?
See More Headlines
Receive ESPR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Esperion Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ESPR Company Calendar

Last Earnings
2/21/2023
Today
3/26/2023
Next Earnings (Estimated)
5/02/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ESPR
CUSIP
N/A
CIK
1434868
Web
www.esperion.com
Phone
(734) 887-3903
Fax
N/A
Employees
218
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$11.17
High Stock Price Forecast
$22.00
Low Stock Price Forecast
$1.50
Forecasted Upside/Downside
+597.9%
Consensus Rating
Hold
Rating Score (0-4)
2.22
Research Coverage
9 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($3.55)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-233,660,000.00
Net Margins
-309.58%
Pretax Margin
-309.58%
Return on Equity
N/A
Return on Assets
-77.40%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.67
Quick Ratio
2.29

Sales & Book Value

Annual Sales
$75.47 million
Price / Sales
1.62
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($4.39) per share
Price / Book
-0.36

Miscellaneous

Outstanding Shares
76,570,000
Free Float
74,046,000
Market Cap
$122.51 million
Optionable
Optionable
Beta
0.25

Key Executives

  • Sheldon L. Koenig
    President, Chief Executive Officer & Director
  • Benjamin Halladay
    Chief Financial Officer
  • Ken Fiorelli
    Chief Technical Operations Officer
  • JoAnne Micale Foody
    Chief Medical Officer
  • William J. Sasiela
    Senior Vice President-Clinical Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













ESPR Stock - Frequently Asked Questions

Should I buy or sell Esperion Therapeutics stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Esperion Therapeutics in the last twelve months. There are currently 2 sell ratings, 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ESPR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ESPR, but not buy additional shares or sell existing shares.
View ESPR analyst ratings or view top-rated stocks.

What is Esperion Therapeutics' stock price forecast for 2023?

9 brokers have issued 1 year price targets for Esperion Therapeutics' shares. Their ESPR share price forecasts range from $1.50 to $22.00. On average, they expect the company's share price to reach $11.17 in the next year. This suggests a possible upside of 597.9% from the stock's current price.
View analysts price targets for ESPR or view top-rated stocks among Wall Street analysts.

How have ESPR shares performed in 2023?

Esperion Therapeutics' stock was trading at $6.23 at the start of the year. Since then, ESPR stock has decreased by 74.3% and is now trading at $1.60.
View the best growth stocks for 2023 here.

When is Esperion Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 2nd 2023.
View our ESPR earnings forecast.

How were Esperion Therapeutics' earnings last quarter?

Esperion Therapeutics, Inc. (NASDAQ:ESPR) announced its quarterly earnings results on Tuesday, February, 21st. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.87) by $0.11. The biopharmaceutical company earned $18.18 million during the quarter, compared to the consensus estimate of $20.60 million. The company's revenue for the quarter was up 18.1% on a year-over-year basis. During the same period last year, the business posted ($1.77) earnings per share.

What ETFs hold Esperion Therapeutics' stock?

ETFs with the largest weight of Esperion Therapeutics (NASDAQ:ESPR) stock in their portfolio include Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), SPDR S&P Pharmaceuticals ETF (XPH), Principal Healthcare Innovators ETF (BTEC) and ProShares Ultra Nasdaq Biotechnology (BIB) and

What is Tim Mayleben's approval rating as Esperion Therapeutics' CEO?

20 employees have rated Esperion Therapeutics Chief Executive Officer Tim Mayleben on Glassdoor.com. Tim Mayleben has an approval rating of 80% among the company's employees.

What other stocks do shareholders of Esperion Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Esperion Therapeutics investors own include ALDW (ALDW), Targa Resources (TRGP), Navios Maritime Partners (NMM), NVIDIA (nvda), Micron Technology (MU), SFL (SFL), Gilead Sciences (GILD), Boeing (BA), Alibaba Group (BABA) and BioMarin Pharmaceutical (bmrn).

What is Esperion Therapeutics' stock symbol?

Esperion Therapeutics trades on the NASDAQ under the ticker symbol "ESPR."

Who are Esperion Therapeutics' major shareholders?

Esperion Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Braidwell LP (4.61%), Two Sigma Investments LP (2.09%), Geode Capital Management LLC (1.74%), ExodusPoint Capital Management LP (1.59%), Norges Bank (1.00%) and Schonfeld Strategic Advisors LLC (0.96%). Insiders that own company stock include Benjamin Looker, Eric Warren, Joanne M Foody, Sheldon L Koenig and Target N V Biotech.
View institutional ownership trends.

How do I buy shares of Esperion Therapeutics?

Shares of ESPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Esperion Therapeutics' stock price today?

One share of ESPR stock can currently be purchased for approximately $1.60.

How much money does Esperion Therapeutics make?

Esperion Therapeutics (NASDAQ:ESPR) has a market capitalization of $122.51 million and generates $75.47 million in revenue each year. The biopharmaceutical company earns $-233,660,000.00 in net income (profit) each year or ($3.55) on an earnings per share basis.

How many employees does Esperion Therapeutics have?

The company employs 218 workers across the globe.

How can I contact Esperion Therapeutics?

Esperion Therapeutics' mailing address is 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108. The official website for the company is www.esperion.com. The biopharmaceutical company can be reached via phone at (734) 887-3903 or via email at ir@esperion.com.

This page (NASDAQ:ESPR) was last updated on 3/26/2023 by MarketBeat.com Staff